利培酮联合丙戊酸钠治疗以阳性症状为主的精神分裂症的临床研究

Clinical study on Risperidone combined with Sodium valproate in treatment of schizophrenic patients with positive symptoms

目的:探讨利培酮联合丙戊酸钠治疗以阳性症状为主的精神分裂症的疗效和安全性。方法:将符合标准的104例患者随机分为对照组与研究组,每组各52例。对照组单用利培酮治疗,研究组联合使用丙戊酸钠治疗。分别于治疗前、治疗后第1、2、3、4周采用阳性和阴性症状量表(PANSS)、副反应量表(TESS)对患者进行评估。结果:两组在治疗第1、2周的疗效差异有统计学意义(P<0.05),治疗结束时两组疗效差异无统计学意义(P>0.05)。两组治疗过程中不良反应比较差异无统计学意义(P>0.05)。结论:丙戊酸钠治疗以阳性症状为主的精神分裂症疗效可靠,可做为常规治疗,而在治疗第4周可考虑逐渐停用丙戊酸钠。

Objective： To investigate efficacy and safety of Sodium valproate combined with Risperidone in the treatment schiz- ophrenic patients with positive symptoms. Methods ： 104 patients meeting with the criteria were randomly divided into control group （ n = 52） and experimental group （n = 52）. The control group was treated with Risperidone alone, while the experimental group was trea- ted with Sodium valproate combined with Risperidone. The patients were assessed by the positive and negative symptom scale （ PAN- SS ） and treatment emergent symptom scale （TESS） before and 1 , 2, 3 and 4 weeks after the treatment. Results ： The difference in the efficacy 1 and 2 weeks after the treatment between the experimental group and the control group was statistically significant （ P〈0.05 ） ; however, the difference at the end of the treatment between the two groups was not statistically significant （P〉0.05）. Further, there were no significant differences in the adverse reactions between the two groups during the treatment （P〉0. 05 ）. Conclusions： It is re- liable to use Sodium valproate in the treatment of the schizophrenic patients with positive symptoms, which can be used as a routine treatment. However, it may consider the gradual discontinuation of Sodium valproate in the fourth week of the treatment.